Gina Vitale

Jan 13, 2025 | inquirer.com | Gina Vitale

I don’t remember the first time I saw the Christmas light show in the Center City Macy’s. I remember the fourth or fifth time, when I was old enough to sit quietly on the floor, because the worst ear infection I ever had arose right in the middle of it. I squeezed my head with my hands on either side, focusing on the lights’ colorful glow, while my father ran out past the giant bronze eagle and over to the nearest CVS.

Nov 10, 2023 | cen.acs.org | Gina Vitale

People with schizophrenia may experience a variety of symptoms, including hallucinations, delusions, or being unable to feel pleasure. They may also have cognitive symptoms; for instance, they may struggle to pay attention or have problems with memory. Kynexis, a new Dutch start-up, is developing a drug that they hope will be able to treat cognitive impairment associated with schizophrenia (CIAS), a condition for which no drugs have been approved. "It's a large population.

Nov 1, 2023 | cen.acs.org | Gina Vitale

Drug designers try many different tricks to degrade badly behaving proteins. Much of the action in that space comes from companies developing small molecules like proteolysis targeting chimeras (PROTACs), which degrade proteins that operate inside the cell. Gate Bioscience, a Versant Ventures-backed start-up that launched today with $60 million in series A funding, has set its sights on disease-causing proteins that are destined for outside the cell.

Oct 31, 2023 | cen.acs.org | Gina Vitale |Brian Gutiérrez

The Nobel Prize announcements are big events at Chemical & Engineering News. But we find out the winners at the same time as everyone else. Then, the race is on for our reporters. This year, staffers Laurel Oldach and Mitch Jacoby took on the task of covering the science prizes. In this episode, they reflect on this year's winning research in chemistry and medicine and share what it's like covering some of the most prestigious prizes in science.

Oct 5, 2023 | cen.acs.org | Gina Vitale

Two recent deals in molecular glues come hot on the heels of the launch of Magnet Biomedicine, a glues-focused start-up. On Sept. 20, Orionis Biosciences said that it would be teaming up with Genentech-owned by Roche-to discover and develop glues; on Sept 26, A-Alpha Bio and Amgen announced that they would be expanding a glue partnership struck last year. Molecular glues are monovalent small molecules that draw two proteins into close proximity with each other.